FEATURE STORY
● Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies
GENE THERAPY
● Permanent inactivation of HBV genomes by CRISPR/Cas9-mdediated non cleavage base editing
DISRUPTIVE TECHNOLOGIES
● Hydroxybutyl chitosan centered biocomposites for potential curative applications
● CAR-T treatment for hematological malignancies
● Anti-CRISPRs : Protein inhibitors of the CRISPR-Cas systems
● Russian company BIOCAD started working on mRNA vaccine against coronavirus
CLINICAL TRIALS – DATA
● Hydroxybutyl chitosan centered biocomposites for potential curative applications
● CAR-T treatment for hematological malignancies
● Anti-CRISPRs : Protein inhibitors of the CRISPR-Cas systems
● Russian company BIOCAD started working on mRNA vaccine against coronavirus
CLINICAL TRIALS – DATA
● Onasemnogene Abeparvovec-xioi: gene therapy for Spinal Muscular Atrophy
● First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors
INDUSTRIAL LANDSCAPE & AGREEMENTS
● AstraZeneca pays Silence $60M to take siRNA beyond the liver
● AstraZeneca pays Silence $60M to take siRNA beyond the liver
● Horama signs exclusive license agreement with Leiden University Medical Center targeting CRB1 gene mutations to treat inherited retinal dystrophies
MISCELLANEOUS
● The ‘Netflix plus model’: can subscription financing improve access to medicines in low- and middle-income countries?
To read the full articles, click here: Trend Chart on Innovative Biotherapies
COMMENTS ARE OFF THIS POST